Tesamorelin (Egrifta SV)
Egrifta SV · TH9507
A stabilized GHRF analog that stimulates pituitary GH release; approval is indication-specific.
Mechanism
Growth hormone–releasing factor analog
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Adults with HIV and excess abdominal fat
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common daily schedule | 1–2 mg | 1–2 mg/day | Once daily | Consistent daily time | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Approved tesamorelin presentations have product-specific vial strengths, supplied diluent and preparation instructions; use the exact label rather than generic math.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Cycle Structure
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Weeks 1–2 | 1 mg per administration | 5 times weekly | 5 mg/week |
| Week 3 onward | 2 mg per administration | 5 times weekly | 10 mg/week |
Peptide Vials
| Cycle | Total compound | Vials needed | How long one vial lasts |
|---|---|---|---|
| 8 weeks | 70 mg | 7 × 10 mg | 2 weeks initially; 1 week after escalation |
| 12 weeks | 110 mg | 11 × 10 mg | 2 weeks initially; 1 week after escalation |
Bacteriostatic Water
| Cycle | Total water used | 10 mL bottles needed |
|---|---|---|
| 8 weeks | 14 mL | 2 × 10 mL |
| 12 weeks | 22 mL | 3 × 10 mL |
Insulin Syringes (U-100)
| Cycle | Administrations | Syringes needed |
|---|---|---|
| 8 weeks | 40 | 40 |
| 12 weeks | 60 | 60 |
The seven-vial 8-week total assumes five administrations per week. Counts are rounded up; water-bottle totals assume 10 mL bottles.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Labeling includes warnings for malignancy, elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.